Subcutaneous immunotherapy for allergic rhinitis: An evidence based review of the recent literature with recommendations

Michael T. Purkey, Timothy Smith, Berrylin J. Ferguson, Amber Luong, William R. Reisacher, Harold C. Pillsbury, Elina Toskala

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Allergic rhinitis is a common allergic disease with increasing prevalence in Western Societies. Medical therapy is first line treatment, and is aimed at reducing symptoms of immunoglobulin E (IgE)-mediated inflammation of the nasal passages. In patients with disease refractory to medical therapy, subcutaneous immunotherapy is an option. The aim of this study is to update a recent Cochrane review with available level 1 evidence for seasonal and perennial allergic rhinitis. Methods: A systematic review of the literature was performed from 2006 to 2011 and compared with data from a 2007 Cochrane review on immunotherapy for seasonal allergic rhinitis. We included all studies of level 1 evidence. All forms of single extract immunotherapy were considered. Studies with primary asthma related end-points were excluded. Primary end-points were instruments of clinical efficacy (ie, symptom-medication scores) and adverse events. Results: We retrieved 12 level 1 studies for review. In total, 1512 patients were randomized into treatment groups, alternative study groups (alternative duration of therapy or sublingual immunotherapy [SLIT]), or placebo. Efficacy was evaluated based on reported symptom and/or medication score, validated quality of life instruments, immunological assays, challenge testing, and adverse events. Conclusion: Subcutaneous immunotherapy improves symptom and/or medication scores and validated quality of life measures. In addition, associated changes in surrogate markers of immunologic protection are observed. Subcutaneous immunotherapy is safe when administered to carefully selected patients and in settings capable of responding to systemic reactions. Subcutaneous immunotherapy is recommended for patients with seasonal or perennial allergic rhinitis not responsive to conservative medical therapy, and whose symptoms significantly affect quality of life.

Original languageEnglish (US)
Pages (from-to)519-531
Number of pages13
JournalInternational Forum of Allergy and Rhinology
Volume3
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Immunotherapy
Seasonal Allergic Rhinitis
Quality of Life
Sublingual Immunotherapy
Therapeutics
Complementary Therapies
Nose
Immunoglobulin E
Allergic Rhinitis
Asthma
Biomarkers
Placebos
Inflammation

Keywords

  • Adverse effects
  • Allergen administration and dosage
  • Allergic rhinitis
  • Desensitization
  • Immunology
  • Pollen
  • Randomized controlled trials
  • Seasonal therapy
  • Subcutaneous immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Subcutaneous immunotherapy for allergic rhinitis : An evidence based review of the recent literature with recommendations. / Purkey, Michael T.; Smith, Timothy; Ferguson, Berrylin J.; Luong, Amber; Reisacher, William R.; Pillsbury, Harold C.; Toskala, Elina.

In: International Forum of Allergy and Rhinology, Vol. 3, No. 7, 07.2013, p. 519-531.

Research output: Contribution to journalArticle

Purkey, Michael T. ; Smith, Timothy ; Ferguson, Berrylin J. ; Luong, Amber ; Reisacher, William R. ; Pillsbury, Harold C. ; Toskala, Elina. / Subcutaneous immunotherapy for allergic rhinitis : An evidence based review of the recent literature with recommendations. In: International Forum of Allergy and Rhinology. 2013 ; Vol. 3, No. 7. pp. 519-531.
@article{10b7a4bb60e84553822c2ea72056ee07,
title = "Subcutaneous immunotherapy for allergic rhinitis: An evidence based review of the recent literature with recommendations",
abstract = "Background: Allergic rhinitis is a common allergic disease with increasing prevalence in Western Societies. Medical therapy is first line treatment, and is aimed at reducing symptoms of immunoglobulin E (IgE)-mediated inflammation of the nasal passages. In patients with disease refractory to medical therapy, subcutaneous immunotherapy is an option. The aim of this study is to update a recent Cochrane review with available level 1 evidence for seasonal and perennial allergic rhinitis. Methods: A systematic review of the literature was performed from 2006 to 2011 and compared with data from a 2007 Cochrane review on immunotherapy for seasonal allergic rhinitis. We included all studies of level 1 evidence. All forms of single extract immunotherapy were considered. Studies with primary asthma related end-points were excluded. Primary end-points were instruments of clinical efficacy (ie, symptom-medication scores) and adverse events. Results: We retrieved 12 level 1 studies for review. In total, 1512 patients were randomized into treatment groups, alternative study groups (alternative duration of therapy or sublingual immunotherapy [SLIT]), or placebo. Efficacy was evaluated based on reported symptom and/or medication score, validated quality of life instruments, immunological assays, challenge testing, and adverse events. Conclusion: Subcutaneous immunotherapy improves symptom and/or medication scores and validated quality of life measures. In addition, associated changes in surrogate markers of immunologic protection are observed. Subcutaneous immunotherapy is safe when administered to carefully selected patients and in settings capable of responding to systemic reactions. Subcutaneous immunotherapy is recommended for patients with seasonal or perennial allergic rhinitis not responsive to conservative medical therapy, and whose symptoms significantly affect quality of life.",
keywords = "Adverse effects, Allergen administration and dosage, Allergic rhinitis, Desensitization, Immunology, Pollen, Randomized controlled trials, Seasonal therapy, Subcutaneous immunotherapy",
author = "Purkey, {Michael T.} and Timothy Smith and Ferguson, {Berrylin J.} and Amber Luong and Reisacher, {William R.} and Pillsbury, {Harold C.} and Elina Toskala",
year = "2013",
month = "7",
doi = "10.1002/alr.21141",
language = "English (US)",
volume = "3",
pages = "519--531",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Subcutaneous immunotherapy for allergic rhinitis

T2 - An evidence based review of the recent literature with recommendations

AU - Purkey, Michael T.

AU - Smith, Timothy

AU - Ferguson, Berrylin J.

AU - Luong, Amber

AU - Reisacher, William R.

AU - Pillsbury, Harold C.

AU - Toskala, Elina

PY - 2013/7

Y1 - 2013/7

N2 - Background: Allergic rhinitis is a common allergic disease with increasing prevalence in Western Societies. Medical therapy is first line treatment, and is aimed at reducing symptoms of immunoglobulin E (IgE)-mediated inflammation of the nasal passages. In patients with disease refractory to medical therapy, subcutaneous immunotherapy is an option. The aim of this study is to update a recent Cochrane review with available level 1 evidence for seasonal and perennial allergic rhinitis. Methods: A systematic review of the literature was performed from 2006 to 2011 and compared with data from a 2007 Cochrane review on immunotherapy for seasonal allergic rhinitis. We included all studies of level 1 evidence. All forms of single extract immunotherapy were considered. Studies with primary asthma related end-points were excluded. Primary end-points were instruments of clinical efficacy (ie, symptom-medication scores) and adverse events. Results: We retrieved 12 level 1 studies for review. In total, 1512 patients were randomized into treatment groups, alternative study groups (alternative duration of therapy or sublingual immunotherapy [SLIT]), or placebo. Efficacy was evaluated based on reported symptom and/or medication score, validated quality of life instruments, immunological assays, challenge testing, and adverse events. Conclusion: Subcutaneous immunotherapy improves symptom and/or medication scores and validated quality of life measures. In addition, associated changes in surrogate markers of immunologic protection are observed. Subcutaneous immunotherapy is safe when administered to carefully selected patients and in settings capable of responding to systemic reactions. Subcutaneous immunotherapy is recommended for patients with seasonal or perennial allergic rhinitis not responsive to conservative medical therapy, and whose symptoms significantly affect quality of life.

AB - Background: Allergic rhinitis is a common allergic disease with increasing prevalence in Western Societies. Medical therapy is first line treatment, and is aimed at reducing symptoms of immunoglobulin E (IgE)-mediated inflammation of the nasal passages. In patients with disease refractory to medical therapy, subcutaneous immunotherapy is an option. The aim of this study is to update a recent Cochrane review with available level 1 evidence for seasonal and perennial allergic rhinitis. Methods: A systematic review of the literature was performed from 2006 to 2011 and compared with data from a 2007 Cochrane review on immunotherapy for seasonal allergic rhinitis. We included all studies of level 1 evidence. All forms of single extract immunotherapy were considered. Studies with primary asthma related end-points were excluded. Primary end-points were instruments of clinical efficacy (ie, symptom-medication scores) and adverse events. Results: We retrieved 12 level 1 studies for review. In total, 1512 patients were randomized into treatment groups, alternative study groups (alternative duration of therapy or sublingual immunotherapy [SLIT]), or placebo. Efficacy was evaluated based on reported symptom and/or medication score, validated quality of life instruments, immunological assays, challenge testing, and adverse events. Conclusion: Subcutaneous immunotherapy improves symptom and/or medication scores and validated quality of life measures. In addition, associated changes in surrogate markers of immunologic protection are observed. Subcutaneous immunotherapy is safe when administered to carefully selected patients and in settings capable of responding to systemic reactions. Subcutaneous immunotherapy is recommended for patients with seasonal or perennial allergic rhinitis not responsive to conservative medical therapy, and whose symptoms significantly affect quality of life.

KW - Adverse effects

KW - Allergen administration and dosage

KW - Allergic rhinitis

KW - Desensitization

KW - Immunology

KW - Pollen

KW - Randomized controlled trials

KW - Seasonal therapy

KW - Subcutaneous immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84880668778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880668778&partnerID=8YFLogxK

U2 - 10.1002/alr.21141

DO - 10.1002/alr.21141

M3 - Article

C2 - 23315962

AN - SCOPUS:84880668778

VL - 3

SP - 519

EP - 531

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 7

ER -